Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen

被引:71
作者
Duc, Le H.
Hong, Huynh A.
Atkins, Helen S.
Flick-Smith, Helen C.
Durrani, Zarmina
Rijpkema, Sjoerd
Titball, Richard W.
Cutting, Simon M. [1 ]
机构
[1] Univ London Royal Holloway & Bedford New Coll, Egham TW20 0EX, Surrey, England
[2] Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England
[3] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England
[4] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
基金
英国生物技术与生命科学研究理事会;
关键词
anthrax; endospores; anthrax vaccine; heat-stable vaccine;
D O I
10.1016/j.vaccine.2006.07.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Protective immunity to anthrax can be achieved by antibodies raised against the secreted protective antigen (PA) and this forms the basis of the current acellular vaccines for human use. Bacillus subtilis spores have previously been used for delivery of heterologous antigens by the oral and nasal routes and their intrinsic heat-stability make them attractive vaccine vehicles. In this study we have expressed PA, or segments of PA, in B. subtilis using two strategies. First, display on the spore coat, and second, in the germinated spore (or vegetative cell). Using parenteral delivery we show that recombinant spores can be used to confer protective immunity in a murine model using an in vitro toxin neutralization assay and a challenge experiment with the latter showing protection to 100 median lethal dose of B. anthracis spores. PA must be secreted from the live bacterium or alternatively displayed on the spore surface to confer protective immunity. Intracellular expression of PA failed to confer protective immunity. The highest levels of protective immunity were achieved when PA was displayed on the spore surface as well as in the germinating spore. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:346 / 355
页数:10
相关论文
共 40 条
  • [1] [Anonymous], 2001, Anal Biochem
  • [2] [Anonymous], 1990, Molecular biological methods for Bacillus, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X
  • [3] The development of new vaccines against Bacillus anthracis
    Baillie, L
    [J]. JOURNAL OF APPLIED MICROBIOLOGY, 2001, 91 (04) : 609 - 613
  • [4] Passive transfer of protection against Bacillus anthracis infection in a murine model
    Beedham, RJ
    Turnbull, PCB
    Williamson, ED
    [J]. VACCINE, 2001, 19 (31) : 4409 - 4416
  • [5] Molecular basis for improved anthrax vaccines
    Brey, RN
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (09) : 1266 - 1292
  • [6] Brossier F, 2002, INFECT IMMUN, V70, P661
  • [7] Bacillus probiotics:: Spore germination in the gastrointestinal tract
    Casula, G
    Cutting, SM
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (05) : 2344 - 2352
  • [8] The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions
    Cote, CK
    Rossi, CA
    Kang, AS
    Morrow, PR
    Lee, JS
    Welkos, SL
    [J]. MICROBIAL PATHOGENESIS, 2005, 38 (5-6) : 209 - 225
  • [9] Bacterial spores as vaccine vehicles
    Duc, L
    Hong, HA
    Fairweather, N
    Ricca, E
    Cutting, SM
    [J]. INFECTION AND IMMUNITY, 2003, 71 (05) : 2810 - 2818
  • [10] Intracellular fate and immunogenicity of B-subtilis spores
    Duc, LH
    Hong, HA
    Uyen, NQ
    Cutting, SM
    [J]. VACCINE, 2004, 22 (15-16) : 1873 - 1885